Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Development of a foundation for a case definition of post-treatment Lyme disease syndrome.

Aucott JN, Crowder LA, Kortte KB.

Int J Infect Dis. 2013 Jun;17(6):e443-9. doi: 10.1016/j.ijid.2013.01.008. Epub 2013 Feb 23.

2.

Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?

Aucott JN, Rebman AW, Crowder LA, Kortte KB.

Qual Life Res. 2013 Feb;22(1):75-84.

3.

CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study.

Aucott JN, Soloski MJ, Rebman AW, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Bechtold KT.

Clin Vaccine Immunol. 2016 Sep 6;23(9):757-66. doi: 10.1128/CVI.00071-16. Print 2016 Sep.

4.

Long-term Assessment of Post-Treatment Symptoms in Patients With Culture-Confirmed Early Lyme Disease.

Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, Cooper D, Nadelman RB, Visintainer P, Schwartz I, Wormser GP.

Clin Infect Dis. 2015 Dec 15;61(12):1800-6. doi: 10.1093/cid/civ735. Epub 2015 Sep 18.

5.

Standardized Symptom Measurement of Individuals with Early Lyme Disease Over Time.

Bechtold KT, Rebman AW, Crowder LA, Johnson-Greene D, Aucott JN.

Arch Clin Neuropsychol. 2017 Mar 1;32(2):129-141. doi: 10.1093/arclin/acw098.

PMID:
28365751
6.

Update of the Swiss guidelines on post-treatment Lyme disease syndrome.

Nemeth J, Bernasconi E, Heininger U, Abbas M, Nadal D, Strahm C, Erb S, Zimmerli S, Furrer H, Delaloye J, Kuntzer T, Altpeter E, Sturzenegger M, Weber R, For The Swiss Society For Infectious Diseases And The Swiss Society For Neurology.

Swiss Med Wkly. 2016 Dec 5;146:w14353. doi: 10.4414/smw.2016.14353. eCollection 2016. Review.

7.

Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice. A randomized controlled trial with a 1-year follow-up.

Eliassen KE, Reiso H, Berild D, Lindbæk M.

Clin Microbiol Infect. 2018 Dec;24(12):1290-1296. doi: 10.1016/j.cmi.2018.02.028. Epub 2018 Mar 2.

PMID:
29505880
8.

The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome.

Rebman AW, Bechtold KT, Yang T, Mihm EA, Soloski MJ, Novak CB, Aucott JN.

Front Med (Lausanne). 2017 Dec 14;4:224. doi: 10.3389/fmed.2017.00224. eCollection 2017.

9.

Posttreatment Lyme disease syndrome.

Aucott JN.

Infect Dis Clin North Am. 2015 Jun;29(2):309-23. doi: 10.1016/j.idc.2015.02.012. Review.

PMID:
25999226
10.

Health care costs, utilization and patterns of care following Lyme disease.

Adrion ER, Aucott J, Lemke KW, Weiner JP.

PLoS One. 2015 Feb 4;10(2):e0116767. doi: 10.1371/journal.pone.0116767. eCollection 2015.

11.

Subjective symptoms after treatment of early Lyme disease.

Cerar D, Cerar T, Ruzić-Sabljić E, Wormser GP, Strle F.

Am J Med. 2010 Jan;123(1):79-86. doi: 10.1016/j.amjmed.2009.05.011.

PMID:
20102996
12.

Functional outcomes in patients with Borrelia burgdorferi reinfection.

Jares TM, Mathiason MA, Kowalski TJ.

Ticks Tick Borne Dis. 2014 Feb;5(1):58-62. doi: 10.1016/j.ttbdis.2013.09.002. Epub 2013 Nov 9.

PMID:
24215678
13.

Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients.

Rebman AW, Crowder LA, Kirkpatrick A, Aucott JN.

Clin Rheumatol. 2015 Mar;34(3):585-9. doi: 10.1007/s10067-014-2706-z. Epub 2014 Jun 13.

PMID:
24924604
14.

Doxycycline versus ceftriaxone for the treatment of patients with chronic Lyme borreliosis.

Ogrinc K, Logar M, Lotric-Furlan S, Cerar D, Ruzić-Sabljić E, Strle F.

Wien Klin Wochenschr. 2006 Nov;118(21-22):696-701.

PMID:
17160610
15.

Persistent Lyme Empiric Antibiotic Study Europe (PLEASE)--design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis.

Berende A, ter Hofstede HJ, Donders AR, van Middendorp H, Kessels RP, Adang EM, Vos FJ, Evers AW, Kullberg BJ.

BMC Infect Dis. 2014 Oct 16;14:543. doi: 10.1186/s12879-014-0543-y.

16.

The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in Belgium.

Geebelen L, Lernout T, Kabamba-Mukadi B, Saegeman V, Sprong H, Van Gucht S, Beutels P, Speybroeck N, Tersago K.

Arch Public Health. 2017 Aug 7;75:42. doi: 10.1186/s13690-017-0202-z. eCollection 2017.

17.

Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease.

Steere AC, Dhar A, Hernandez J, Fischer PA, Sikand VK, Schoen RT, Nowakowski J, McHugh G, Persing DH.

Am J Med. 2003 Jan;114(1):58-62. No abstract available.

PMID:
12543291
18.

Symptom load and general function among patients with erythema migrans: a prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice.

Eliassen KE, Hjetland R, Reiso H, Lindbæk M, Tschudi-Madsen H.

Scand J Prim Health Care. 2017 Mar;35(1):75-83. doi: 10.1080/02813432.2017.1288812. Epub 2017 Feb 28.

19.

Lyme disease vs Baggio-Yoshinari syndrome in a returned traveller from Brazil.

Vien VP, Bassi R, Maxim T, Bogoch II.

J Travel Med. 2017 Sep 1;24(5). doi: 10.1093/jtm/tax055. No abstract available.

PMID:
28931143
20.

Comparison of post-Lyme Borreliosis symptoms in erythema migrans patients with positive and negative Borrelia burgdorferi sensu lato skin culture.

Stupica D, Lusa L, Cerar T, Ružić-Sabljić E, Strle F.

Vector Borne Zoonotic Dis. 2011 Jul;11(7):883-9. doi: 10.1089/vbz.2010.0018. Epub 2010 Nov 17.

PMID:
21083376

Supplemental Content

Support Center